APA (7th ed.) Citation

Bridgewater, J., Gardini, A. C., Wilmink, H., Mercade, T. M., Sim, H., Verslype, C., . . . Rimassa, L. (2025). 262MO Preliminary efficacy outcomes of ivosidenib in patients with IDH1-mutated cholangiocarcinoma (mIDH1 CCA): Initial results from the phase IIIb ProvIDHe study. Annals of Oncology, 36, S103. https://doi.org/10.1016/j.annonc.2025.05.277

Chicago Style (17th ed.) Citation

Bridgewater, J.A, et al. "262MO Preliminary Efficacy Outcomes of Ivosidenib in Patients with IDH1-mutated Cholangiocarcinoma (mIDH1 CCA): Initial Results from the Phase IIIb ProvIDHe Study." Annals of Oncology 36 (2025): S103. https://doi.org/10.1016/j.annonc.2025.05.277.

MLA (9th ed.) Citation

Bridgewater, J.A, et al. "262MO Preliminary Efficacy Outcomes of Ivosidenib in Patients with IDH1-mutated Cholangiocarcinoma (mIDH1 CCA): Initial Results from the Phase IIIb ProvIDHe Study." Annals of Oncology, vol. 36, 2025, p. S103, https://doi.org/10.1016/j.annonc.2025.05.277.